Australian surveillance finds similar short-term AEFI rates with MVA-BN co-administration

An Australian active-surveillance study compared adverse events after MVA-BN mpox vaccination alone or with other vaccines in 10,943 adults. Reported adverse events were similar or less frequent among the 200 participants who received a concomitant vaccine, although the findings are exploratory and the cohort was predominantly male.

10,943 adults completed both post-vaccination surveys.
Only 200 participants received a concomitant vaccine.
AEFI rates were similar or lower with co-administration.
Findings are exploratory and predominantly reflect adult men.

Researchers used AusVaxSafety surveillance data to assess adverse events following immunisation (AEFIs) among adults who received MVA-BN in Australia from August 2022 to April 2023. Participants were surveyed 7 and 14 days after vaccination; analyses included 10,943 people who completed both surveys. Outcomes were compared by dose, administration route and whether another vaccine was given at the same time. The response rate was 46%, and 97% of participants were male; 200 (1.8%) received at least one concomitant vaccine.

Within 14 days, AEFI rates among intradermal recipients were 56% versus 53% after dose 1 and 36% versus 32% after dose 2, for MVA-BN alone versus co-administration, respectively. For subcutaneous administration, rates were 49% versus 28% after dose 1 and 32% versus 24% after dose 2. Medical review was uncommon (0–2.7%), and most symptoms lasted no more than one day. Impact on daily activities was reported by 6% of those vaccinated alone and 3.5% of concomitant recipients.

The findings offer preliminary real-world evidence that short-term AEFI frequency and severity were similar with and without co-administration. The small concomitant-vaccination group, 46% survey response rate and predominantly male population limit interpretation and generalisability; the study does not establish safety for every vaccine combination or population.

In practice

For adults receiving MVA-BN mpox vaccine, this Australian surveillance study found no higher observed rate of short-term adverse events when another vaccine was given concomitantly. This is preliminary evidence rather than definitive guidance: only 200 of 10,943 participants received a concomitant vaccine, the response rate was 46%, and 97% of participants were male. Results may not generalise to other populations or all vaccine combinations, and do not establish that every combination has equivalent safety.

AI-generated clinical interpretation · Not editor-reviewed

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Source

Eurosurveillance: Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023 ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.